Screener
TG Therapeutics TGTX Share Buybacks
Share Buybacks at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfEquity.
The source filing: TG Therapeutics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-015246
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Proceeds from exercise of options | 763 | 21 |
| Proceeds from debt financings, net of debt discount costs | 747,656 | — |
| Financing costs paid | (2,598) | — |
| Purchase of treasury stock | (99,992) | (6,123) |
| Net cash provided by (used in) financing activities | 390,829 | (6,102) |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 363,071 | (47,751) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 80,490 | 181,192 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | $443,561 | $133,441 |
Document
FAQ
- What is TG Therapeutics's share buybacks?
- TG Therapeutics (TGTX) reported share buybacks of $99.99M in Q1 2026.
- How has TG Therapeutics's share buybacks changed year-over-year?
- TG Therapeutics's share buybacks increased by 1533.1% year-over-year, from $6.12M to $99.99M.
- What does share buybacks mean?
- Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.
Ask your AI about TG Therapeutics's share buybacks.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude